<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00094497</url>
  </required_header>
  <id_info>
    <org_study_id>CO-ACT-001</org_study_id>
    <nct_id>NCT00094497</nct_id>
    <nct_alias>NCT00924144</nct_alias>
  </id_info>
  <brief_title>Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)</brief_title>
  <official_title>First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Collaborative Group for Adrenocortical Carcinoma Treatment</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Collaborative Group for Adrenocortical Carcinoma Treatment</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment with etoposide, doxorubicin,
      cisplatin and mitotane (EDP/M) prolongs survival as compared to streptozotocin and mitotane
      (Sz/M) in patients with advanced adrenocortical carcinoma (ACC) whose disease is not amenable
      to complete surgical resection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Firm-ACT trial is the first ever conducted randomized controlled phase III trial in
      adrenocortical carcinoma (ACC), a rare malignancy with poor prognosis. It will provide
      results leading to the establishment of an urgently needed gold standard chemotherapy regimen
      for patients with locally advanced or metastatic ACC. To this end the trial compares the two
      most promising drug combinations investigated in phase II trials, considered by the
      &quot;International Consensus Conference on Adrenal Cancer&quot; (Ann Arbor/USA, 2003) as valuable
      first line treatments for advanced ACC. The first regimen consists of etoposide, doxorubicin,
      cisplatin plus mitotane (EDP-M), the second regiment employs streptozotocin plus mitotane
      (Sz-M). Over a period of five years this international trial will include 300 patients with
      advanced ACC from different European countries. Blood mitotane concentrations will be
      monitored, aiming at drug levels between 14 - 20 mg/L. Patients not responding to the first
      line treatment will be switched to the alternative regimen. The primary objective of this
      trial is to investigate whether EDP-M given as first line treatment will prolong survival as
      compared to Sz-M. Secondary endpoints are quality of life, time to progression, best overall
      response rate and duration of response. In addition, the trial evaluates the role of reaching
      therapeutic mitotane serum concentrations for survival and tumour response and assesses the
      value of the two alternative treatment regimens as second line therapy in advanced ACC.
      Moreover, the FIRM-ACT trial will generate a lasting structural basis for successful future
      trials in ACC.

      In a substudy of 40 patients a detailed analysis of the pharmacokinetics of oral mitotane
      will be analysed. Two different mitotane treatment regimens (&quot;low dose&quot; vs. &quot;high dose&quot;) will
      be compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>every 8 weeks until death up to 5 years</time_frame>
    <description>participants who died among those randomized to first-line therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>every 8 weeks until progression or death up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life as Measured by QLQ-C30</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>scale ranged from 0 to 100 with higher score meaning greater quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response Rate</measure>
    <time_frame>every 8 weeks up to 5 years</time_frame>
    <description>RECIST 1.0 was used to evaluate response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Disease-free Patients</measure>
    <time_frame>every 8 weeks until progression (up to 5 years)</time_frame>
    <description>complete response or disease-free by time of surgery</description>
  </secondary_outcome>
  <other_outcome>
    <measure>TTP of Both Regimens as Second Line Treatment in Case of Failure of the Other Initial Regime</measure>
    <time_frame>every 8 weeks until progression or until Dec 2010</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pharmakinetics of Mitotane (Substudy)</measure>
    <time_frame>11 time points in the first 12 weeks</time_frame>
    <description>To study the relationship between mitotane dose (daily and cumulative) and mitotane plasma concentrations using one of two pre-defined treatment regimens (high-dose and low-dose).</description>
  </other_outcome>
  <other_outcome>
    <measure>Impact of Reaching Mitotane Blood Levels Between 14-20 mg/l in Both Arms on Survival and Overall Response Rate</measure>
    <time_frame>every 8 weeks until progression or until Dec 2010</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">304</enrollment>
  <condition>Carcinoma, Adrenal Cortical</condition>
  <arm_group>
    <arm_group_label>EDP-M</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>etopodide, doxorubicin, cisplatin and mitotane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sz-M</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>streptozotocin and mitotane</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <arm_group_label>EDP-M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <arm_group_label>EDP-M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>EDP-M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Streptozotocin</intervention_name>
    <arm_group_label>Sz-M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitotane</intervention_name>
    <arm_group_label>EDP-M</arm_group_label>
    <arm_group_label>Sz-M</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of adrenocortical carcinoma

          -  Locally advanced or metastatic disease not amenable to radical surgery resection
             (Stage III-IV)

          -  Radiologically monitorable disease

          -  ECOG performance status 0-2

          -  Life expectancy &gt; 3 months

          -  Age ≥18 years

          -  Adequate bone marrow reserve (neutrophils &gt; 1500/mm3 and platelets &gt; 100,000/mm3)

          -  Effective contraception in pre-menopausal female and male patients

          -  Patient's written informed consent

          -  Ability to comply with the protocol procedures (including availability for follow-up
             visits)

          -  Previous palliative surgery, radiotherapy or radiofrequency ablation is acceptable as
             long as radiologically monitorable disease is verifiable afterwards.

        Exclusion Criteria:

          -  History of prior malignancy, except for cured non-melanoma skin cancer, curatively in
             situ cervical carcinoma, or other cancers treated with no evidence of disease for at
             least five years.

          -  Previous cytotoxic chemotherapy for adrenocortical carcinoma

          -  Renal insufficiency (serum creatinine ≥2 mg/dl or creatinine clearance ≤ 50 ml/min)

          -  Hepatic insufficiency (serum bilirubin ≥2 x the institutional upper limit of normal
             range and/or serum transaminases ≥ 3 x the institutional upper limit of normal range;
             exception: in patients on mitotane, transaminase levels up to 5 x the institutional
             upper limit of normal range are acceptable)

          -  Pregnancy or breast feeding

          -  Known hypersensitivity to any drug included in the treatment protocol

          -  Presence of active infection

          -  Any other severe clinical condition that in the judgment of the local investigator
             would place the patient at undue risk or interfere with the study completion

          -  Decompensated heart failure (ejection fraction &lt;50%), myocardial infarction or
             revascularization procedure during the last 6 months, unstable angina pectoris, and
             uncontrolled cardiac arrhythmia

          -  Current treatment with other experimental drugs and/or previous participation in
             clinical trials with other experimental agents for adrenocortical carcinoma

          -  Prisoners
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Britt Skogseid, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Uppsala University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Fassnacht, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Würzburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Institute - Center for Cancer Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan, Department of Internal Medicine</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <zip>SA 5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Marc Linquette</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Marseille la timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Bordeaux haut leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité-University, Dept. of Endocrinology; Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité-Universitätsmedizin Berlin - Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Medicine III</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Duesseldorf, Dept. of Endocrrinology</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40001</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Innere Medizin - Endokrinologie des Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endokrinologie Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-von-Guericke University; Dept. of Endocrinology</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Medicine I</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Munich, Dept. of Internal Medicine (Innenstadt)</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wuerzburg - Dept. of Medicine</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Turin, Dept of Internal Medicine</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Endocrinologica, Università di Padova, Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1007</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum; Dept. of Endocrinology</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum; Dept. of Internal Medicine</name>
      <address>
        <city>Eindhoven</city>
        <zip>5631 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Groningen; Dept. of Internal Medine</name>
      <address>
        <city>Groningen</city>
        <zip>9700</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, The Jubileum Institute, Lund University</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Surgery, Karolinska Hospital, Stockholm</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital - Dept of Medical Sciences</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.firm-act.org</url>
    <description>Click here for more information about this study: First International Randomized trial in locally advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)</description>
  </link>
  <results_reference>
    <citation>Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardière C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Müller HH, Skogseid B; FIRM-ACT Study Group. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012 Jun 7;366(23):2189-97. doi: 10.1056/NEJMoa1200966. Epub 2012 May 2.</citation>
    <PMID>22551107</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2004</study_first_submitted>
  <study_first_submitted_qc>October 19, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2004</study_first_posted>
  <results_first_submitted>September 19, 2016</results_first_submitted>
  <results_first_submitted_qc>September 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 21, 2016</results_first_posted>
  <last_update_submitted>September 19, 2016</last_update_submitted>
  <last_update_submitted_qc>September 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Collaborative Group for Adrenocortical Carcinoma Treatment</investigator_affiliation>
    <investigator_full_name>Martin Fassnacht</investigator_full_name>
    <investigator_title>Co-PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adrenocortical Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Mitotane</mesh_term>
    <mesh_term>Streptozocin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>EDP-M</title>
          <description>etopodide, doxorubicin, cisplatin and mitotane
Etoposide
Doxorubicin
Cisplatin
Mitotane
participants who progressed during first line therapy, were eligible to the alternative treatment (Sz-M)</description>
        </group>
        <group group_id="P2">
          <title>Sz-M</title>
          <description>streptozotocin and mitotane
Streptozotocin
Mitotane
participants who progressed during first line therapy, were eligible to the alternative treatment (EDP-M)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Second Line Therapy</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>EDP-M</title>
          <description>etopodide, doxorubicin, cisplatin and mitotane
Etoposide
Doxorubicin
Cisplatin
Mitotane
participants who progressed during first line therapy, were eligible to the alternative treatment (Sz-M)</description>
        </group>
        <group group_id="B2">
          <title>Sz-M</title>
          <description>streptozotocin and mitotane
Streptozotocin
Mitotane
participants who progressed during first line therapy, were eligible to the alternative treatment (EDP-M)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="151"/>
            <count group_id="B2" value="153"/>
            <count group_id="B3" value="304"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;= 18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>tumor stage</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG</title>
          <description>Eastern Cooperative Oncology Group performance status score (ranges from 0, asymptomatic - 5, dead)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>participants who died among those randomized to first-line therapy</description>
        <time_frame>every 8 weeks until death up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EDP-M</title>
            <description>etopodide, doxorubicin, cisplatin and mitotane
Etoposide
Doxorubicin
Cisplatin
Mitotane
participants who progressed during first line therapy, were eligible to the alternative treatment (Sz-M)</description>
          </group>
          <group group_id="O2">
            <title>Sz-M</title>
            <description>streptozotocin and mitotane
Streptozotocin
Mitotane
participants who progressed during first line therapy, were eligible to the alternative treatment (EDP-M)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>participants who died among those randomized to first-line therapy</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <time_frame>every 8 weeks until progression or death up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EDP-M</title>
            <description>etopodide, doxorubicin, cisplatin and mitotane
Etoposide
Doxorubicin
Cisplatin
Mitotane
participants who progressed during first line therapy, were eligible to the alternative treatment (Sz-M)</description>
          </group>
          <group group_id="O2">
            <title>Sz-M</title>
            <description>streptozotocin and mitotane
Streptozotocin
Mitotane
participants who progressed during first line therapy, were eligible to the alternative treatment (EDP-M)</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="3.5" upper_limit="6.9"/>
                    <measurement group_id="O2" value="2.1" lower_limit="2.04" upper_limit="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life as Measured by QLQ-C30</title>
        <description>scale ranged from 0 to 100 with higher score meaning greater quality of life</description>
        <time_frame>baseline and 8 weeks</time_frame>
        <population>participants with data on both time points</population>
        <group_list>
          <group group_id="O1">
            <title>EDP-M</title>
            <description>etopodide, doxorubicin, cisplatin and mitotane
Etoposide
Doxorubicin
Cisplatin
Mitotane
participants who progressed during first line therapy, were eligible to the alternative treatment (Sz-M)</description>
          </group>
          <group group_id="O2">
            <title>Sz-M</title>
            <description>streptozotocin and mitotane
Streptozotocin
Mitotane
participants who progressed during first line therapy, were eligible to the alternative treatment (EDP-M)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life as Measured by QLQ-C30</title>
          <description>scale ranged from 0 to 100 with higher score meaning greater quality of life</description>
          <population>participants with data on both time points</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="21.4"/>
                    <measurement group_id="O2" value="-7.7" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Overall Response Rate</title>
        <description>RECIST 1.0 was used to evaluate response</description>
        <time_frame>every 8 weeks up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EDP-M</title>
            <description>etopodide, doxorubicin, cisplatin and mitotane
Etoposide
Doxorubicin
Cisplatin
Mitotane
participants who progressed during first line therapy, were eligible to the alternative treatment (Sz-M)</description>
          </group>
          <group group_id="O2">
            <title>Sz-M</title>
            <description>streptozotocin and mitotane
Streptozotocin
Mitotane
participants who progressed during first line therapy, were eligible to the alternative treatment (EDP-M)</description>
          </group>
        </group_list>
        <measure>
          <title>Best Overall Response Rate</title>
          <description>RECIST 1.0 was used to evaluate response</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>disease-free by time of surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>did not receive treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>could not be evaluated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Disease-free Patients</title>
        <description>complete response or disease-free by time of surgery</description>
        <time_frame>every 8 weeks until progression (up to 5 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EDP-M</title>
            <description>etopodide, doxorubicin, cisplatin and mitotane
Etoposide
Doxorubicin
Cisplatin
Mitotane
participants who progressed during first line therapy, were eligible to the alternative treatment (Sz-M)</description>
          </group>
          <group group_id="O2">
            <title>Sz-M</title>
            <description>streptozotocin and mitotane
Streptozotocin
Mitotane
participants who progressed during first line therapy, were eligible to the alternative treatment (EDP-M)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Disease-free Patients</title>
          <description>complete response or disease-free by time of surgery</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>TTP of Both Regimens as Second Line Treatment in Case of Failure of the Other Initial Regime</title>
        <time_frame>every 8 weeks until progression or until Dec 2010</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmakinetics of Mitotane (Substudy)</title>
        <description>To study the relationship between mitotane dose (daily and cumulative) and mitotane plasma concentrations using one of two pre-defined treatment regimens (high-dose and low-dose).</description>
        <time_frame>11 time points in the first 12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Impact of Reaching Mitotane Blood Levels Between 14-20 mg/l in Both Arms on Survival and Overall Response Rate</title>
        <time_frame>every 8 weeks until progression or until Dec 2010</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 5 years</time_frame>
      <desc>Other non-serious adverse events were not reliably collected and therefore not reported</desc>
      <group_list>
        <group group_id="E1">
          <title>EDP-M</title>
          <description>etopodide, doxorubicin, cisplatin and mitotane
Etoposide
Doxorubicin
Cisplatin
Mitotane
participants who progressed during first line therapy, were eligible to the alternative treatment (Sz-M)</description>
        </group>
        <group group_id="E2">
          <title>Sz-M</title>
          <description>streptozotocin and mitotane
Streptozotocin
Mitotane
participants who progressed during first line therapy, were eligible to the alternative treatment (EDP-M)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>bone marrow toxicity</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue or general health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>impaired liver function</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>neurologic toxicity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>impaired renal function</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>cardiovascular or thromboembolic events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Martin Fassnacht</name_or_title>
      <organization>University Hospital of Wuerzburg, Germany</organization>
      <phone>+49-931-201-39021</phone>
      <email>fassnacht_m@ukw.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

